SCHEMBL10286758

SCHEMBL10286758

C=C(C)c1cc2ncc(C(=O)OC)c(N)n2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CYP2C19 P33261 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
CYP2C9 P11712 2/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 7/20 0.39
CYP1A2 P05177 3/20 0.38
KDM4E B2RXH2 6/20 0.37
TSHR P16473 2/20 0.37
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HPGD P15428 2/20 0.35
CFTR P13569 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3262344 0.86 NPC1 (0.61) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL237417 0.81 CYP1A2 (0.55) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL2755207 0.81 NPC1 (0.52) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL2755168 0.80 NPC1 (0.46) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL2755218 0.79 NPC1 (0.46) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL3253086 0.77 PKM (0.32) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL2755116 0.76 NPC1 (0.47) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL2755224 0.75 NPC1 (0.59) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL2755212 0.75 RAB9A (0.65) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A
SCHEMBL2755219 0.74 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.